Top 20 of Cerebrovascular Disorders

Article title # Publications/# Citations

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

1995:

664

The Cardiovascular Health Study: design and rationale.

1991: NOBorhani; PEnright; LPFried; CDFurberg; JMGardin; RAKronmal; LHKuller; TAManolio; MBMittelmark; ANewman;

611

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

1998:

523

Mortality by cause for eight regions of the world: Global Burden of Disease Study.

1997: ADLopez; CJMurray;

375

Pathobiology of ischaemic stroke: an integrated view.

1999: UDirnagl; CIadecola; MAMoskowitz;

369

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.

1999: GLBurke; RAKronmal; TAManolio; DHO'Leary; JFPolak; SKWolfson;

368

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

1991: RDAbbott; WBKannel; PAWolf;

328

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

1990: RAbbott; RCollins; JCutler; ADyer; JGodwin; SMacMahon; JNeaton; RPeto; PSorlie; JStamler;

306

Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.

1991: North American Symptomatic Carotid Endarterectomy Trial Collaborators;

275

The blood-brain barrier/neurovascular unit in health and disease.

2005: TPDavis; BTHawkins;

271

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

1998: EJBenjamin; RBD'Agostino; WBKannel; DLevy; HSilbershatz; PAWolf;

262

Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

1990: RCollins; KAEberlein; NHFiebach; JGodwin; PHébert; CHHennekens; SMacMahon; RPeto; NQizilbash; JOTaylor;

260

Interobserver agreement for the assessment of handicap in stroke patients.

1988: PJKoudstaal; HJSchouten; Jvan Gijn; JCvan Swieten; MCVisser;

260

The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance.

1975: ARFugl-Meyer; LJääskö; ILeyman; SOlsson; SSteglind;

255

Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group.

1989:

251

PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis.

2005: EDAbel; CBernal-Mizrachi; SBoudina; ZChen; MCourtois; BNFinck; JOHolloszy; DPKelly; ... JJLehman; TCLeone; DMMedeiros; JESaffitz; NSambandam; PJSchaeffer; RESchmidt; CFSemenkovich; ARWende; DFWozniak;

226

Long-term exposure to air pollution and incidence of cardiovascular events in women.

2007: GLAnderson; JDKaufman; KAMiller; KShepherd; LSheppard; DSSiscovick; JHSullivan;

219

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

1991:

218

Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study.

1995: DEBild; PMCrowley; RGCruise; ALFitzpatrick; DGIves; LHKuller; BMPsaty; STheroux;

212

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

1994:

208